Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of molecular profiling and drug research using artificial intelligence.
Source link
By Daniel snow
Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of molecular profiling and drug research using artificial intelligence.
Source link
